![]() ![]() By using the Site, you are indicating that you are at least eighteen (18) years old and have the legal authority to accept the Terms of Use. Furthermore, by using the Site you agree to execute any and all documents that are necessary to make use of the Site, and the services offered through the Site, available to you. ![]() As the Terms of Use may be revised from time to time, you should review them periodically. If you do not agree with the Terms of Use, please do not use the Site. ![]() Access to and use of the Site are subject to the following terms and conditions and all applicable laws (collectively, "Terms of Use"). The Site contains information about Alpha drug, a product of Lash. ("Lash") and administered and operated by The Lash Group, Inc. The study, “Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis1-Year Results From the RELIEVE-AD Study,” was published online in JAMA Dermatology.Welcome to Lash Group Provider Portal (the "Site"), a website for services arranged by The Lash Group, Inc. “These results are consistent with those observed in clinical trials and expand on the sustained benefits that may be expected with dupilumab over the course of long-term treatment,” the team wrote. Investigators believed their data was consistent with patient-reported outcomes in clinical trials. Promisingly, the of other therapies for atopic dermatitis was reduced at each follow-up compared to baseline, including topical and systemic corticosteroids which were reduced at month 12 to 40.4% (195 of 483 patients) and 6.2% (30 of 483 patients), respectively.Īdditionally, patient satisfaction with treatment was higher than baseline (120 of 699 ) at each follow-up to 85.1% (411 of 483) at month 12 ( P < .001). However, cost issues were cited by 16 patients, while insurance coverage was cited by 12. Investigators evaluated a total of 699 patients, 632 (90.4%) of whom completed the survey during the first month and 483 (69.1%) who completed it at month 12.ĭiscontinuation of dupilumab was reported by 93 (13.3%) patients, with 17 restarting therapy, resulting in an overall discontinuation rate of 10.9%.Īdverse effects and a lack of efficacy were considered the most common reasons for discontinuation at 22 (3.1%) and 25 (3.6%) patients, respectively. The Dermatology Life Quality Index (DLQI) was used to evaluate health-related quality of life. Medical history was also acquired in the form of atopic comorbidities of asthma, eosinophilic esophagitis, nasal polyps, and nonseasonal allergies.ĭisease control was assessed using the Atopic Dermatitis Control Tool (ADCT), which included 6 questions that evaluated the severity of atopic dermatitis. The dupilumab patient support program was designed to give patients better access to the biologic as well as provide services including copay assistance programs, nurse educator support, and supplemental injection training.Patient outreach was initiated on January 2018, with the final survey at the 12-month time point completed on January 2020.Įligibility criteria included being 18 years or older, able to speak and read in English, and had not previously participated in a dupilumab trial or treated with the biologic.Īdditionally, sociodemographic, disease characteristics, and prior atopic dermatitis treatment history were collected at baseline. The RELIEVE-AD study was a prospective, longitudinal cohort study intended to characterize patient experiences in the clinical practice setting with dupilumab over a 12-month period.Įligible patients were adults with atopic dermatitis who were prescribed with the biologic in routine clinical practice in the US before being enrolled in the dupilumab patient support program. Investigators led by Bruce Strober, MD, PhD, Yale University School of Medicine, New Haven, cited several clinical trials of patients with moderate-to-severe atopic dermatitis in which dupilumab significantly reduced itch and improved clinical and patient-reported outcomes relative to placebo.įor the RELIEVE-AD study, patient experience was evaluated in the clinical setting regarding disease control and quality of life during the first year following dupilumab initiation, in addition to potential benefits beyond those seen in the clinical trial setting. This was demonstrated by statistically significant improvements relative to baseline on all patient-reported outcomes including treatment satisfaction. New data from the year-long RELIEVE-AD study concluded that dupilumab treatment was associated with rapid and sustained disease control in adult patients with atopic dermatitis for up to 12 months.
0 Comments
Leave a Reply. |